國電科環(01296.HK)及龍源技術擬按比例對望奎新能源增資
格隆匯8月11日丨國電科環(01296.HK)公佈,鑑於首次注資已撥付到位,且望奎新能源已於2021年8月5日召開2021年第一次臨時股東會,審議通過了首次注資事項,根據中國相關法規,首次注資已完成。
於2021年8月11日,公司、龍源技術及望奎新能源訂立二次注資協議,據此,公司及龍源技術同意按其各自於望奎新能源的持股比例分別向望奎新能源新增資本人民幣5655萬元及人民幣3045萬元。緊隨二次注資完成後,望奎新能源的註冊資本將由人民幣1.23億元增加至人民幣2.1億元,望奎新能源將繼續由公司及龍源技術分別擁有65%及35%的股權。緊隨完成二次注資後,望奎新能源仍為公司附屬公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.